GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Enterprise Value

Genetic Technologies (Genetic Technologies) Enterprise Value : $8.25 Mil (As of May. 01, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genetic Technologies's Enterprise Value is $8.25 Mil. Genetic Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Genetic Technologies's EV-to-EBIT ratio for today is .

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Genetic Technologies's Enterprise Value is $8.25 Mil. Genetic Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Genetic Technologies's EV-to-EBITDA ratio for today is .

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Genetic Technologies's Enterprise Value is $8.25 Mil. Genetic Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Genetic Technologies's EV-to-Revenue ratio for today is .


Genetic Technologies Enterprise Value Historical Data

The historical data trend for Genetic Technologies's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Enterprise Value Chart

Genetic Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.90 19.08 48.04 10.07 11.07

Genetic Technologies Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.32 - 11.07 - 6.99

Competitive Comparison of Genetic Technologies's Enterprise Value

For the Diagnostics & Research subindustry, Genetic Technologies's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Enterprise Value falls into.



Genetic Technologies Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Genetic Technologies's Enterprise Value for the fiscal year that ended in Jun. 2023 is calculated as

Genetic Technologies's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Technologies  (NAS:GENE) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Genetic Technologies's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=8.248/0
=

Genetic Technologies's current Enterprise Value is $8.25 Mil.
Genetic Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Genetic Technologies's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=8.248/0
=

Genetic Technologies's current Enterprise Value is $8.25 Mil.
Genetic Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Genetic Technologies's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8.248/0
=

Genetic Technologies's current Enterprise Value is $8.25 Mil.
Genetic Technologies's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Technologies Enterprise Value Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies (Genetic Technologies) Business Description

Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.